Eli Lilly's Orforglipron Approval Delayed to April
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2026
0mins
Source: NASDAQ.COM
- Approval Delay: Eli Lilly's oral GLP-1 candidate, orforglipron, has seen its FDA review timeline extended from the end of February to April 10, resulting in a roughly 4% drop in the company's stock price in one day, indicating a negative market reaction to the news.
- Intensifying Competition: Novo Nordisk has already launched its oral Wegovy after receiving approval in December, positioning itself to capture market share from patients hesitant about injectable options, thereby increasing competitive pressure on Eli Lilly.
- Positive Market Outlook: Despite the delay in orforglipron's approval, Eli Lilly maintains a strong leadership position in the weight loss market, with an attractive mid- and late-stage pipeline in its core therapeutic area, indicating long-term potential in the rapidly growing sector.
- Strong Financial Performance: Eli Lilly's financial results remain robust, and the company offers a generous dividend program, suggesting that the market may have overreacted to the FDA's extended review, with the stock still viewed as a buying opportunity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1160.950
Low
950.00
Averages
1192
High
1500
Current: 1160.950
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Weight-Loss Pill Approved in the UK
- Regulatory Approval: The UK's Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk's Wegovy weight-loss pill, providing over 10 million obese patients with a new needle-free treatment option, significantly enhancing Novo's competitive edge in the market.
- Market Potential: With obesity affecting approximately 30% of adults, equating to an estimated 13 to 14 million people, the approval of Wegovy is expected to drive demand for weight-loss medications and reshape the pharmaceutical landscape.
- Eligibility Criteria: The pill is approved for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 with at least one related condition, and is anticipated to be available through private prescriptions within weeks, broadening patient access.
- Industry Impact: Wegovy contains the same active ingredient, semaglutide, as Novo's blockbuster injectable drugs, which is expected to accelerate the company's leadership in the weight-loss market while increasing competitive pressure on rivals like Eli Lilly.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
Viking Therapeutics Stock Potential Analysis
- Market Potential: Viking Therapeutics' stock has surged over 300% in the past five years, despite recent declines, indicating strong potential in the nearly $100 billion weight loss drug market, with significant revenue growth expected in the coming years.
- Clinical Trial Progress: The company anticipates reporting data from its maintenance dosing study in Q3 and plans to launch a phase 3 trial for the oral version in Q4, which could serve as catalysts for a stock rebound.
- Product Differentiation Advantage: Viking's VK2735 is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formats, and if approved, it would be the first drug to offer both formulations, catering to diverse patient needs.
- Market Reaction Potential: Viking's stock has shown sensitivity to news, previously soaring over 100% in a single day following phase 2 data release, suggesting that positive updates could propel the stock towards the $100 target.
See More
Viking Therapeutics Advances in Weight Loss Drug Development
- Massive Market Potential: Viking Therapeutics is developing candidates in the weight loss drug market, projected to reach nearly $100 billion in the coming years; although the company has yet to commercialize any drugs, its lead candidate VK2735 is in late-stage studies, indicating strong market prospects.
- Clinical Trial Progress: Viking plans to launch a phase 3 trial for the oral version of VK2735 in Q4 and expects to report data from a maintenance dosing study in Q3, with these catalysts potentially driving stock price recovery, especially after a decline over the past year.
- Product Differentiation Advantage: VK2735, as the first dual GLP-1/GIP receptor agonist available in both injectable and oral forms, can cater to varying patient needs during weight loss, potentially attracting more users and generating significant revenue for the company.
- Stock Price Recovery Expectations: Despite Viking's current stock price of about $27, Wall Street's average estimate suggests it could rise above $92 within the next 12 months, representing over 200% growth potential, reflecting optimistic market sentiment regarding its future performance.
See More
SpaceX Sets Record for Largest U.S. IPO
- Innovative IPO Pricing: SpaceX priced its IPO at $135 per share, raising a record $75 billion and achieving a valuation of $1.77 trillion, making it one of the world's most valuable companies and reflecting strong market confidence in its growth prospects.
- Enhanced Market Position: Following its IPO, SpaceX will rank seventh on Nasdaq, surpassing major firms like JPMorgan and Berkshire Hathaway in valuation despite last year's losses, indicating investor recognition of its long-term potential.
- Retail Investor Engagement: By allocating 30% of shares to retail investors, significantly higher than industry norms, SpaceX aims to broaden its shareholder base and enhance market liquidity, demonstrating its commitment to ordinary investors.
- Future Growth Potential: SpaceX's market opportunity is estimated at $28.5 trillion, primarily driven by its Starlink internet service, which connects millions of customers across 164 countries, with future revenue expected to increase through its cloud services agreement with Google.
See More
Novo Nordisk's Weight-Loss Pill Approved in the UK
- Regulatory Approval: The UK's Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk's Wegovy weight-loss pill, providing over 10 million obese patients with a new needle-free treatment option, significantly enhancing Novo's competitive edge in the market.
- Market Potential: With obesity affecting approximately 30% of adults, equating to an estimated 13 to 14 million people, the approval of Wegovy is expected to drive demand for weight-loss medications and reshape the pharmaceutical landscape.
- Eligibility Criteria: The pill is approved for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 with at least one related condition, and is anticipated to be available through private prescriptions within weeks, broadening patient access.
- Industry Impact: Wegovy contains the same active ingredient, semaglutide, as Novo's blockbuster injectable drugs, which is expected to accelerate the company's leadership in the weight-loss market while increasing competitive pressure on rivals like Eli Lilly.
See More
AbbVie Showcases New Data in Blood Cancer Portfolio
- Dividend Appeal: AbbVie's dividend yield exceeds 3%, significantly higher than the sub-2% yields of blue-chip healthcare stocks like Eli Lilly, Johnson & Johnson, and Amgen, indicating strong cash flow support that helps attract investors and bolster market confidence.
- EHA Conference Presentation: At the European Hematology Association Congress, AbbVie showcased 21 clinical data presentations on various blood cancers, enhancing its reputation in the treatment space and potentially facilitating future regulatory approvals and partnerships, thereby driving revenue growth.
- Diversified Revenue Streams: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, helping to reduce reliance on Humira and enhancing overall business resilience, ensuring sustained cash flow to support dividend payments.
- Ongoing R&D Investment: AbbVie is actively investing in expanding existing therapies and developing next-generation treatments, aiming to create new revenue sources through successful clinical trials, ensuring that oncology continues to be a growth driver and further solidifying its dividend-paying capacity.
See More
AbbVie Expands Blood Cancer Treatment Market with New Data
- Market Expansion Potential: AbbVie showcased 21 research data points on blood cancers at the European Hematology Association Congress, covering various types including chronic lymphocytic leukemia, which could open new indications for existing drugs and drive future revenue growth.
- Revenue Diversification: In 2025, AbbVie's oncology portfolio generated approximately $6.7 billion in revenue, highlighting its significance as a revenue source despite the focus on immunology, thereby supporting R&D and dividend payments.
- Risk Management Strategy: In response to the challenges posed by Humira's patent expiration, AbbVie has aggressively built new growth platforms across immunology, oncology, and neuroscience, reducing dependence on any single product and enhancing cash flow resilience.
- Clinical Trial Outlook: AbbVie continues to invest in expanding existing therapies into new indications and advancing next-generation blood cancer treatments, with successful clinical trials creating potential for new approvals, larger patient populations, and longer revenue runways, ensuring long-term cash flow to support dividend growth.
See More
Viking Therapeutics Stock Potential Analysis
- Market Potential: Viking Therapeutics' stock has surged over 300% in the past five years, despite recent declines, indicating strong potential in the nearly $100 billion weight loss drug market, with significant revenue growth expected in the coming years.
- Clinical Trial Progress: The company anticipates reporting data from its maintenance dosing study in Q3 and plans to launch a phase 3 trial for the oral version in Q4, which could serve as catalysts for a stock rebound.
- Product Differentiation Advantage: Viking's VK2735 is a dual GLP-1/GIP receptor agonist being developed in both injectable and oral formats, and if approved, it would be the first drug to offer both formulations, catering to diverse patient needs.
- Market Reaction Potential: Viking's stock has shown sensitivity to news, previously soaring over 100% in a single day following phase 2 data release, suggesting that positive updates could propel the stock towards the $100 target.
See More
Viking Therapeutics Advances in Weight Loss Drug Development
- Massive Market Potential: Viking Therapeutics is developing candidates in the weight loss drug market, projected to reach nearly $100 billion in the coming years; although the company has yet to commercialize any drugs, its lead candidate VK2735 is in late-stage studies, indicating strong market prospects.
- Clinical Trial Progress: Viking plans to launch a phase 3 trial for the oral version of VK2735 in Q4 and expects to report data from a maintenance dosing study in Q3, with these catalysts potentially driving stock price recovery, especially after a decline over the past year.
- Product Differentiation Advantage: VK2735, as the first dual GLP-1/GIP receptor agonist available in both injectable and oral forms, can cater to varying patient needs during weight loss, potentially attracting more users and generating significant revenue for the company.
- Stock Price Recovery Expectations: Despite Viking's current stock price of about $27, Wall Street's average estimate suggests it could rise above $92 within the next 12 months, representing over 200% growth potential, reflecting optimistic market sentiment regarding its future performance.
See More
SpaceX Sets Record for Largest U.S. IPO
- Innovative IPO Pricing: SpaceX priced its IPO at $135 per share, raising a record $75 billion and achieving a valuation of $1.77 trillion, making it one of the world's most valuable companies and reflecting strong market confidence in its growth prospects.
- Enhanced Market Position: Following its IPO, SpaceX will rank seventh on Nasdaq, surpassing major firms like JPMorgan and Berkshire Hathaway in valuation despite last year's losses, indicating investor recognition of its long-term potential.
- Retail Investor Engagement: By allocating 30% of shares to retail investors, significantly higher than industry norms, SpaceX aims to broaden its shareholder base and enhance market liquidity, demonstrating its commitment to ordinary investors.
- Future Growth Potential: SpaceX's market opportunity is estimated at $28.5 trillion, primarily driven by its Starlink internet service, which connects millions of customers across 164 countries, with future revenue expected to increase through its cloud services agreement with Google.
See More
